Section II: Attitudes .

Please Indicate How Much You Agree or Disagree With the Following Statements:		Strongly Agree	Somewhat Agree	Neither Agree or Disagree	Somewhat Disagree	Strongly Disagree
6	The costs of new cancer drugs currently influence my decisions regarding which cancer treatments to recommend for my patients
7	The costs of new cancer drugs currently influence my patients’ ability to access treatments.
8	Patient “out-of-pocket” drug costs currently influence my decisions regarding which cancer treatments to recommend for my patients.
9	Patient “out-of-pocket” drug costs currently influence my patients’ ability to access treatments.
10	I feel well-prepared to interpret and use cost-effectiveness information in my treatment decisions.
11	Every Iranian patient should have access to effective cancer treatments regardless of their cost.
12	Every Iranian patient should have access to effective cancer treatments only if the treatments provide “good value for money” or are cost-effective.
13	Over the next 5 years, costs of new cancer drugs will impose a need for governments to further restrict publicly funded access to some new and effective therapies.
14	Government price controls for cancer drugs are needed.
15	More cost-sharing by patients for payment of cancer drugs is needed.
16	More use of cost-effectiveness data in funding decisions for cancer drugs is needed.
17	More research on the comparative effectiveness of cancer drugs is needed.

18- How often do you discuss the costs of cancer treatments with your patients? (Please check answer)

□Always □Frequently □Occasionally □Rarely □Never

19- Who do you believe should determine whether a drug provides good value? (Please check all that apply)

□Ministry of health

□Patients

□Insurance companies

□Academic groups (research centers and scientific societies)

□Other (please specify): ………………